Log In
Print
BCIQ
Print
Print this Print this
 

PPI-383

  Manage Alerts
Collapse Summary General Information
Company Presidio Pharmaceuticals Inc.
DescriptionNon-nucleoside HCV NS5B polymerase inhibitor
Molecular Target HCV NS5B polymerase
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I
Standard IndicationHepatitis C virus (HCV)
Indication DetailsTreat HCV infection
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$100.7M

$100.7M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today